<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01494922</url>
  </required_header>
  <id_info>
    <org_study_id>EXC 001-206</org_study_id>
    <secondary_id>B5301003</secondary_id>
    <nct_id>NCT01494922</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of EXC 001 in Subjects Who Have Participated in Prior Studies of EXC 001</brief_title>
  <official_title>A Phase 2, Open-label Study to Provide Revision of Scars Resulting From Surgery in Prior Studies of EXC 001 (Currently Called PF-06473871)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide subjects who participated in prior studies of EXC 001
      the opportunity to have their hypertrophic scars surgically revised and treated with EXC 001.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the safety of EXC 001 in subjects undergoing elective revision of scars from prior surgery</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physician Scar Assessment Scale</measure>
    <time_frame>Wk 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Scar Assessment Scale</measure>
    <time_frame>Wk 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Reported Scar Severity Scale (Photonumeric Guide)</measure>
    <time_frame>Wk 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Reported Scar Severity Scale (Photonumeric Guide)</measure>
    <time_frame>Wk 24</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Reduction in Severity of Skin Scarring</condition>
  <arm_group>
    <arm_group_label>Open Label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EXC 001 (currently called PF-06473871)</intervention_name>
    <description>Single dose administered by injection at four different times</description>
    <arm_group_label>Open Label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adults who have participated in previous studies of EXC 001.

          -  Healthy adults who have chosen to have their scars revised.

        Exclusion Criteria:

          -  Currently pregnant or pregnant during the 6 months prior to inclusion in the study, or
             breast feeding.

          -  Participation in another clinical trial within 30 days prior to the start of the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tualatin</city>
        <state>Oregon</state>
        <zip>97062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=EXC001-206&amp;StudyName=Safety%20and%20Efficacy%20of%20EXC%20001%20in%20Subjects%20Who%20Have%20Participated%20in%20Prior%20Studies%20of%20EXC%20001</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2011</study_first_submitted>
  <study_first_submitted_qc>December 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2011</study_first_posted>
  <disposition_first_submitted>October 15, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>November 6, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 20, 2014</disposition_first_posted>
  <last_update_submitted>November 6, 2014</last_update_submitted>
  <last_update_submitted_qc>November 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Skin scarring</keyword>
  <keyword>cicatrix</keyword>
  <keyword>hypertrophic scar</keyword>
  <keyword>hypertrophic scar prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cicatrix</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

